This article is a correction to:
Establishment of Tumor Treating Fields Combined With Mild Hyperthermia as Novel Supporting Therapy for Pancreatic Cancer
Liping Bai1†
Tobias Pfeifer1
Wolfgang Gross1
Carolina De La Torre2
Shuyang Zhao3Li Liu1
Michael Schaefer1‡
Ingrid Herr1*‡- 1Molecular OncoSurgery, Section Surgical Research, Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany
- 2Medical Research Center, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany
- 3Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany
A Corrigendum on
Establishment of Tumor Treating Fields Combined With Mild Hyperthermia as Novel Supporting Therapy for Pancreatic Cancer
By Bai L, Pfeifer T, Gross W, De La Torre C, Zhao S, Liu L, Schaefer M and Herr I (2021). Front. Oncol. 11:738801. doi: 10.3389/fonc.2021.738801
In the original article, there was a mistake in Figure 2A as published. The representative images of colony formation “AsPC-1/CO/38.5°C, 1st generation” and “BxGEM/CO/38.5°C, 2nd generation” were mixed up by mistake. The corrected Figure 2 appears below.
FIGURE 2
Figure 2 TTField-mediated inhibition of cancer stem cell features is enhanced by hyperthermia. (A) The cells were treated as described in Figures 1A, B, (B) After 3 days, the cells were detached from the cell culture plates by trypsinization and reseeded at clonal density (AsPC-1: 1,500 cells/well; BxPC-3 and Bx-GEM: 1,000 cells/well) in 6-well plates. The cells were cultured under regular conditions at 37°C without a medium change for 2 weeks, resulting in first-generation colonies (1st GEN). The number of colonies was evaluated by fixing and Coomassie staining, followed by counting colonies with at least 50 cells using a dissecting microscope. The survival fraction and representative images are shown on the left. For the formation of second-generation (2nd GEN) colonies, surviving cells from each group of firstgeneration colonies were collected, reseeded and analyzed as described above. (B) After treatment, as described in Figure 1A, the cells were seeded at a clonal density of 500 cells/well in ultralow-attachment 24-well plates in cell growth factor-supplemented serum-free culture medium to induce spheroid formation. Six dayslater, the first generation of spheroids developed, and the percentage of viable spheroids was evaluated by microscopy at 100× magnification and counting. Representative photographs and the means are shown on the left. For the formation of second-generation spheroids (2nd GEN), surviving cells were collected from each group of first-generation spheroids and reseeded and analyzed as described above. The data are presented as the means ± SDs. *P < 0.05, **P < 0.01.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: pancreatic ductal adenocarcinoma, hyperthermia, tumor treating fields, alternative therapies, bioinformatics and computational biology
Citation: Bai L, Pfeifer T, Gross W, De La Torre C, Zhao S, Liu L, Schaefer M and Herr I (2022) Corrigendum: Establishment of Tumor Treating Fields Combined With Mild Hyperthermia as Novel Supporting Therapy for Pancreatic Cancer. Front. Oncol. 12:889215. doi: 10.3389/fonc.2022.889215
Received: 03 March 2022; Accepted: 14 March 2022;
Published: 31 March 2022.
Edited and reviewed by:
Michael Jon Pishvaian, Johns Hopkins Medicine, United StatesCopyright © 2022 Bai, Pfeifer, Gross, De La Torre, Zhao, Liu, Schaefer and Herr. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ingrid Herr, i.herr@uni-heidelberg.de
†Present address: Liping Bai, Department of Gastrointestinal Surgery, The Affiliated Zhongshan Hospital, and Institute of Gastrointestinal Oncology, School of Medicine, Xiamen University, Xiamen, China
‡These authors share last authorship